Critical Survey: HeartSciences (NASDAQ:HSCS) vs. Movano (NASDAQ:MOVE)

Movano (NASDAQ:MOVE) and HeartSciences (NASDAQ:HSCS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Valuation and Earnings

This table compares Movano and HeartSciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Movano	$1.01 million	6.89	-$23.73 million	($10.83)	-0.77
HeartSciences	N/A	N/A	-$8.77 million	($6.88)	-0.34

HeartSciences has lower revenue, but higher earnings than Movano. Movano is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

16.6% of Movano shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 10.4% of Movano shares are owned by company insiders. Comparatively, 1.8% of HeartSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Movano has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.57, indicating that its stock price is 157% more volatile than the S&P 500.

Profitability

This table compares Movano and HeartSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Movano	-3,409.60%	-647.91%	-225.03%
HeartSciences	N/A	-388.12%	-161.65%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Movano and HeartSciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Movano	1	0	0	0	1.00
HeartSciences	1	0	1	0	2.00

HeartSciences has a consensus target price of $9.00, indicating a potential upside of 281.36%. Given HeartSciences’ stronger consensus rating and higher possible upside, analysts clearly believe HeartSciences is more favorable than Movano.

Summary

HeartSciences beats Movano on 11 of the 13 factors compared between the two stocks.

About Movano

Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.

About HeartSciences

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.